drugset / Trial / NCT01725230

Assess the Pharmacokinetics of Rosuvastatin and Simvastatin When Administered Alone or in Combination With Fostamatinib

NCT01725230

Phase 1 Completed 42 enrolled AstraZeneca
Non-randomizedCrossoverOpen-labelBasic science

Summary

A study to Assess the Pharmacokinetics of Rosuvastatin and Simvastatin when administered alone or in combination with Fostamatinib.

Timeline

Start
2012-11
Primary completion
2013-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Rosuvastatin Small molecule 20 mg Oral
Subject Simvastatin Small molecule 40 mg Oral
Background Fostamatinib Small molecule 100 mg Oral

Indications